Astria Therapeutics, Inc. (ATXS)

Market Cap	321.68M
Revenue (ttm)	n/a
Net Income (ttm)	-94.26M
Shares Out	56.43M
EPS (ttm)	-1.68
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	141,646
Open	6.05
Previous Close	6.06
Day's Range	5.68 - 6.00
52-Week Range	5.68 - 14.04
Beta	0.68
Analysts	Strong Buy
Price Target	26.60 (+366.67%)
Earnings Date	Mar 11, 2025

About ATXS

Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder assoc...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 25, 2015
• Employees: 78
• Stock Exchange: NASDAQ
• Ticker Symbol: ATXS
• Website: https://www.astriatx.com

Analyst Forecast

According to 5 analysts, the average rating for ATXS stock is "Strong Buy." The 12-month stock price forecast is $26.6, which is an increase of 366.67% from the latest price.

Price Target

$26.6

(366.67% upside)

Analyst Consensus: Strong Buy